Actively Recruiting
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-11
65
Participants Needed
7
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).
CONDITIONS
Official Title
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with multiple myeloma meeting IMWG criteria with measurable disease
- Standard-risk multiple myeloma without high-risk cytogenetic abnormalities
- Eligible for high-dose chemotherapy and autologous stem cell transplant
- Age 18 years or older
- ECOG performance status 0 to 2
- Adequate organ and blood function including hemoglobin ≥7.5 g/dL, ANC ≥1.0 x 10^9/L, platelets ≥75 x 10^9/L, creatinine clearance ≥30 ml/min, bilirubin ≤2x ULN, AST and ALT ≤2.5x ULN
- Able to tolerate thromboprophylaxis with aspirin, low molecular weight heparin, warfarin, or direct oral anticoagulants
- Registered and willing to comply with REMS program, including contraception requirements
You will not qualify if you...
- More than one cycle of prior systemic treatment for multiple myeloma (except corticosteroids or radiation)
- Diagnosis of plasma cell leukemia, primary light chain amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS syndrome, or Waldenström's macroglobulinemia
- Active other primary cancer within 2 years except treated skin cancers or carcinoma in situ
- Significant uncontrolled comorbidities such as COPD with FEV1 <50%, moderate/severe asthma within 2 years, infiltrative lung disease, active autoimmune disease needing immunosuppressants (except some exceptions), severe psychiatric conditions, HIV infection
- Hepatitis B or C infection without sustained virologic response
- Significant heart disease including recent myocardial infarction, unstable angina, advanced heart failure, or uncontrolled arrhythmia
- Pregnant or lactating
- Unwilling or unable to give informed consent or comply with the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
N
Neha Korde, MD
CONTACT
C
Carlyn Rose Tan, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here